PUBLISHER: Orion Market Research | PRODUCT CODE: 1778448
PUBLISHER: Orion Market Research | PRODUCT CODE: 1778448
Gastrointestinal Catheters Market Size, Share & Trends Analysis Report by Product Type (Nasogastric Tubes, Percutaneous Endoscopic Gastrostomy (PEG) Tube, Gastrostomy Tubes (G-Tubes), Jejunostomy Tubes (J-Tubes), Gastrojejunostomy Tubes (GJ-Tubes), Rectal Catheters, Ileus Tube, and Others), and by Application (Enteral Feeding, Decompression and Drainage, Diagnostics and Therapeutic ), and by End-User (Hospitals & Clinics, Ambulatory Surgical Centers (ASCs), Long-Term Care Facilities, and Home Care Settings) Forecast Period (2025-2035)
Industry Overview
Gastrointestinal catheters market is anticipated to reach $5.5 billion in 2035 from $3.4 billion in 2024, growing at a CAGR of 4.5% during the forecast period (2025-2035). The increase in gastrointestinal diseases, the need for minimally invasive procedures, advancement in catheter technology, and the increase in the population of elderly people are all drivers of the increase in GI disorders. Healthcare expenditure and infrastructure in emerging economies are increasing, coupled with awareness of enteral feeding tubes. Government policies and regulatory support ensure the safety and efficacy of GI catheters.
Market Dynamics
Technological Advancements
Advances in catheter technology and materials have produced flexible, durable, biocompatible medical devices with antimicrobial surfaces and onboard sensors, propelling growth in the market for diagnostic and therapeutic uses. For instance, in May 2024, Laborie launched the Solar Compact System and Solar Anorectal Manometry Catheter, the first disposable HRAM catheters, for improved gastrointestinal diagnostics. The instruments record static and dynamic pressures in the lower gastrointestinal tract, increasing diagnostic potential for defecatory disorders and pelvic-floor dysfunction. The cost-effective and portable solar compact system simplifies pharyngeal, esophageal, and anorectal motility studies, following the International Anorectal Physiology Working Group protocol. The software provides customizable procedures and reports.
Rising GI Disorders
Crohn's disease and ulcerative colitis are inflammatory bowel diseases that result in chronic inflammation and damage to the gastrointestinal tract and produce symptoms such as chronic diarrhea, abdominal pain, and weight loss. Crohn's disease involves the gastrointestinal tract, the ileum, and the colon. It appears in patches, affecting some areas and leaving others untouched. Furthermore, inflammation can extend through the bowel wall. The prevalence of gastrointestinal disorders such as Crohn's disease, GERD, and colorectal cancer is on the rise. According to the Crohn's & Colitis Foundation, in 2024, inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, affected approximately 1.6 million Americans, with the majority diagnosed before age 35. The chronic conditions are not curable; however, they are treatable, influencing patients' quality of life and creating significant economic burdens. According to the Olmsted County study, 780,000 individuals in the US have Crohn's disease, and 907,000 have ulcerative colitis, most of whom are diagnosed between 15 and 35 years of age; the median age of diagnosis is 34.9 years for ulcerative colitis and 29.5 years for Crohn's disease.
Market Segmentation
Percutaneous Endoscopic Gastrostomy (PEG) Tube Segment to Lead the Market with the Largest Share
A PEG tube is a surgical procedure that inserts a feeding tube directly into the stomach for long-term nutrition when oral intake is not feasible or sufficient. A PEG tube, or G-tube, is a feeding tube for patients with dysphagia, inadequate nutrition, or body nutrient processing conditions. PEG tube insertion is a minimally invasive procedure used for conditions such as brain injury, head and neck cancer, stroke, chronic loss of appetite, neurological disorders, burn, cystic fibrosis, abdominal cancer, prolonged coma, and HIV/AIDS. PEG tubes offer a safer, more effective option compared to nasogastric tubes and laparotomy-assisted feeding by decreasing the risk of aspiration, distress, and improving the quality of life of patients and caregivers.
Diagnostics: A Key Segment in Market Growth
Gastrointestinal catheters are essential medical devices for diagnosing, monitoring, and treating gastrointestinal tract disorders, evaluating gastrointestinal motility, detecting abnormalities, and guiding therapeutic intervention.GI catheters are employed in a range of diagnostic uses, such as esophageal manometry, antroduodenal manometry, colonic manometry, pH and impedance monitoring, nutritional and enteral access, and endoscopic and radiologic guidance. It is used to monitor esophageal pressure, assess stomach and small bowel motor function, detect acid reflux, and facilitate nutrition in patients with swallowing dysfunction. It further assists in contrast studies and endoscopic retrograde cholangiopancreatography for imaging and diagnostic reasons. GI catheters yield reliable diagnostic information, minimally invasive testing, treatment planning, and long-term gastrointestinal function monitoring, allowing proper diagnosis, treatment planning, and continuous ambulatory monitoring.
The global gastrointestinal catheters market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
Rising Incidence of Gastrointestinal Tract (GIT) cancers in Asia-Pacific
The increase in GIT cancer incidence across the globe has promoted increased demand for state-of-the-art diagnostic and treatment technologies, accelerating the market growth. As reported by the Indian Government, in November 2024, researchers at IITGN designed a new hydrogel platform to enhance the treatment process of GIT cancers. The hydrogel developed is made in India, and it forms a stable cushion during endoscopic interventions, boosting precise and secure treatments. This innovation can revolutionize disease-responsive intelligent drug delivery systems and enhance patient quality of life and survival. The gel material may sustain its cushion-like structure, retain high amounts of water and respond to the increase in GIT cancers globally.
North America Region Dominates the Market with Major Share
North America holds a significant share, owing to the growing prevalence of gastrointestinal disorders necessitates advanced diagnostic and therapeutic tools, driving market growth in specialized catheters. For instance, in January 2025, QIAGEN secured US clearance for its first QIAstat-Dx mini gastrointestinal panel, the QIAstat-Dx Gastrointestinal Panel 2 Mini B&V (bacterial and viral), which is designed to provide fast answers for outpatient diagnosis of gastrointestinal conditions. The panel covers five causes of gastrointestinal illness recommended by the Infectious Diseases Society of America (IDSA), such as Campylobacter, Salmonella, Shiga-like toxin E. coli (STEC), Shigella, and Norovirus. The panel is the first in a series of QIAstat-Dx Gastrointestinal Panel tests for clinical use, supporting QIAGEN's strategy to improve patient treatment options in this important market. It intends to file the QIAstat-Dx rise high-capacity instrument version for FDA approval in early 2025.
The major companies operating in the global gastrointestinal catheters market include Abbott Laboratories, B. Braun SE, Boston Scientific Corp., Medtronic Inc., and Olympus Corp., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments